Immunome (NASDAQ:IMNM) Given New $30.00 Price Target at Stephens

Immunome (NASDAQ:IMNM) had its target price decreased by Stephens from $33.00 to $30.00 in a research note released on Wednesday,Benzinga reports. Stephens currently has an overweight rating on the stock.

Other equities analysts also recently issued reports about the stock. Evercore upped their target price on shares of Immunome from $18.00 to $40.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 16th. Lake Street Capital boosted their price target on Immunome from $22.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Guggenheim increased their price objective on Immunome from $25.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Truist Financial initiated coverage on Immunome in a research report on Monday, December 1st. They set a “buy” rating and a $36.00 target price for the company. Finally, HC Wainwright started coverage on Immunome in a report on Thursday, February 12th. They issued a “buy” rating and a $40.00 target price for the company. Eleven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $32.33.

Immunome Stock Up 4.5%

IMNM stock opened at $22.52 on Wednesday. Immunome has a twelve month low of $5.15 and a twelve month high of $27.65. The firm has a market cap of $2.48 billion, a price-to-earnings ratio of -9.31 and a beta of 2.12. The business’s fifty day simple moving average is $22.78 and its two-hundred day simple moving average is $17.58.

Immunome (NASDAQ:IMNM) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.10). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 75.83%. Research analysts expect that Immunome will post -2.21 EPS for the current year.

Insider Activity at Immunome

In other news, CEO Clay B. Siegall bought 4,729 shares of Immunome stock in a transaction on Tuesday, December 30th. The stock was acquired at an average cost of $21.15 per share, for a total transaction of $100,018.35. Following the completion of the acquisition, the chief executive officer owned 665,254 shares of the company’s stock, valued at $14,070,122.10. This trade represents a 0.72% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Philip Tsai acquired 10,000 shares of the business’s stock in a transaction dated Friday, December 19th. The stock was purchased at an average cost of $20.49 per share, for a total transaction of $204,900.00. Following the transaction, the insider owned 43,300 shares in the company, valued at approximately $887,217. The trade was a 30.03% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 68,518 shares of company stock valued at $1,453,958 over the last quarter. 7.69% of the stock is owned by corporate insiders.

Institutional Trading of Immunome

A number of institutional investors have recently made changes to their positions in IMNM. Assetmark Inc. acquired a new position in Immunome during the 3rd quarter valued at about $39,000. BNP Paribas Financial Markets grew its stake in shares of Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after acquiring an additional 2,909 shares during the last quarter. Strs Ohio purchased a new stake in shares of Immunome during the fourth quarter worth about $64,000. Tower Research Capital LLC TRC increased its holdings in shares of Immunome by 121.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock valued at $65,000 after acquiring an additional 3,802 shares in the last quarter. Finally, BIT Capital GmbH purchased a new position in shares of Immunome in the 3rd quarter valued at approximately $69,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.